Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARONE: Remigromig in DME and NVAMD
NCT05919693Phase 2Completed
- Sponsor
- EyeBio
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) (10 arms), sponsored by EyeBio. Primary endpoints: Dose-limiting Toxicity at 12 weeks, Adverse Event at 12 weeks and 3 more. Started Jun 2023; status: completed.
02
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05919693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919693.